tbuckley/cabot-search huggingface dataset:
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
Authors: Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Jorge J. Castillo
Journal: American Journal of Hematology (2020)

Abstract Disease Overview Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches. Diagnosis The diagnosis is made through a careful pathological evaluation. Detection of EBV‐encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined. The differential diagnosis includes plasmablastic lymphoma (PBL), DLBCL associated with chronic inflammation and primary effusion lymphoma (PEL), among others. Risk‐Stratification The International Prognostic Index (IPI) and the Oyama score can be used for risk‐stratification. The Oyama score includes age &gt;70 years and presence of B symptoms. The expression of CD30 and PD‐1/PD‐L1 are emerging as potential adverse but targetable biomarkers. Management Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. EBV+ DLBCL, NOS, however, might have a worse prognosis than EBV‐negative DLBCL in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS.
Abstract 15790: Hippo Pathway Effector TEAD1 Promotes Direct Cardiac Reprogramming
Authors: Vivek P Singh, Jaya Pratap Pinnamaneni, Aarthi Pugazenthi, Deepthi Sanagasetti, Ayman Almousa, Megumi Mathison, Kai Wang, Abdussalam Elsenousi, Alexis E Shafii, Jianchang Yang, James F Martin, Todd K Rosengart
Journal: Circulation (2019)

Introduction: Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells (iCMs) in situ represents a promising strategy for cardiac regeneration. Hypothesis: Modification of reprogr...
Feasibility of precision cancer medicine in advanced gynaecologic cancers
Authors: H. Taghizadeh, R.M. Mader, L. Müllauer, S. Aust, S. Polterauer, A. Reinthaller, H. Kölbl, V. Seebacher, C. Grimm, G. Prager
Journal: Annals of Oncology (2019)
Efficient Topical Steroid Delivery to Grades 1 and 2 Nasal Polyps in the Osteomeatal Complex (OMC): Deposition Patterns With Exhalation Delivery System (EDS) and Conventional Intranasal Spray (INS) Visualized With Fluorescein in Silicone Cast
Authors: John Bosso, James Palmer, Per Djupesland, German Guerrero, Harry Sacks
Journal: Journal of Allergy and Clinical Immunology (2020)
Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation
Authors: Ian Johnston, Amrita Sarkar, Vincent Hayes, Gavin T. Koma, Gowthami M. Arepally, Junmei Chen, Dominic W. Chung, José A. López, Douglas B. Cines, Lubica Rauova, Mortimer Poncz
Journal: Blood (2020)
Germline DNA copy number polymorphism to predict the efficacy of BCG therapy for non-muscle invasive bladder cancer.
Authors: Yoshiaki Yamamoto, Sho Ozawa, Masahiro Samoto, Junichi Mori, Ryo Inoue, Seiji Yano, Hiroshi Hirata, Hiroaki Matsumoto, Hideyasu Matsuyama
Journal: Journal of Clinical Oncology (2020)

431 Background: Bacillus Calmette-Guerin (BCG) intravesical instillation is the most effective immunotherapy for non-muscle-invasive bladder cancer (NMIBC), however there are few reliable markers to elucidate the efficacy of BCG therapy. Germline copy number polymorphisms (CNPs) are expected to affect various diseases including human malignancies, but the significance of CNPs in NMIBC treated with BCG therapy remains unclear. FAM81A located on 15q22.2 was reported as one of tumor-associated ETS shared target genes in prostate cancer. PCSK6 located on 15q26.3 was reported to regulate proliferation and tumor progression in several cancers. The purpose of this study is to determine the prognostic value of CNPs for NMIBC treated with BCG therapy. To our knowledge, this is the first report to confirm CNPs as a potential biomarker for assessing the efficacy of immunotherapy. Methods: Array comparative genomic hybridization (CGH) was performed to search for candidate whole genome-wide CNPs related to NMIBC susceptibility. Next, quantitative real-time polymerase chain reaction was carried out to evaluate the effect of BCG therapy for 57 Japanese patients with NMIBC treated with BCG intravesical instillation. Results: Eleven CNPs were associated with NMIBC risk in array CGH. FAM81A and PCSK6 copy number according to those CNPs examined showed significant relationship with disease progression in NMIBC treated with BCG. The means of the relative copy numbers of patients with CNP and those without it were 1.58 and 2.10 for FAM81A ( P &lt; 0.0001), and 1.06 and 1.80 for PCSK6 ( P &lt; 0.0001), respectively. Univariate Cox proportional hazards regression analysis showed that FAM81A ( P = 0.0022), and PCSK6 ( P = 0.0147) copy number had a significant effect on progression-free survival. In multivariate analyses, FAM81A copy number was an independent prognostic factor for progression-free survival ( P = 0.0419, RR = 7.59, 95% CI, 1.07–153.42). The combination of FAM81A or PCSK6 CNP was the most significant prognostic biomarker to predict the efficacy of BCG therapy for NMIBC ( P = 0.0002). Conclusions: Germline DNA CNPs may be a potential new biomarker for estimating the efficacy of BCG therapy in Japanese patients with NMIBC.
Feasibility of Oral Administration of S-1 for Adjuvant Chemotherapy of Gastric Cancer; 4-week S-1 Administration followed by 2-week rest vs. 2-week Administration followed by 1-Week Rest
Authors: T. Yamatsuji, Y. Fujiwara, H. Matsumoto, S. Hato, T. Namikawa, K. Hanazaki, M. Ninomiya, T. Fujiwara, T. Hirai, Y. Naomoto
Journal: Annals of Oncology (2012)
Differential tumor growth, drug sensitivity, and gene expression profiles in human-derived 3D biomatrix culture system
Authors: Eric Seales, Maria Belousova, Martin Klinger, David Hamrick, Raj Singh
Journal: Cancer Research (2007)

3009  Three-dimensional (3D) tumor studies mostly employ animal-derived biomatrix culture systems (collagen I, Matrigel), which however pose many limitations. We recently created a novel human-derived biomatrix system, HuBiogel, which in contrast to others, contains all major matrix components and is growth factor (GF)-free. Moreover, this physiologically-relevant culture system supports growth, organization and differentiation of a variety of cell types. In the present study, viable multi-cellular tumor spheroids (1.0-1.5 mm) of human breast (MDA-231) and colon adenocarcinoma (HT-29) cells were produced in HuBiogel and Matrigel. Using 3-15 day coculture protocols, cell proliferation (ATPLite assay), cancer biomarker gene expression (SuperArray) and drug sensitivity (Taxol, Cisplatin) profiles of tumor spheroids were measured. MDA-231 and HT-29 tumor spheroids exhibited 2-3 fold higher proliferation rates in Matrigel vs. HuBiogel. A focused micorarray analysis of breast tumor spheroids revealed higher expression in HuBiogel vs. Matrigel of cell cycle markers (CDK4), differentiation factors (IGFBP3), apoptosis regulators (BIRC5, BNIP3, CDC25B) and kinases (AKT1, PFKP). In contrast, expression levels of biomarkers for cell proliferation (TGFB3, SHBG, RRM2) and a protease implicated in cancer invasion/migration (CTSB) were higher in Matrigel vs. HuBiogel spheroids. Exposure of tumor spheroids to two known therapeutic agents, Taxol and Cisplatin, resulted in an interesting drug sensitivity pattern which depended upon both treatment regimens and biomatrix nature/composition of tumor spheroids. Our findings elucidate that i) 3D cell-matrix environment is a dynamic regulator of tumorigenesis and ii) defined stromal-epithelial signals control tumor cell behavior, and thereby, drug responsiveness. We conclude that HuBiogel culture model better emulates tumor biology in vitro, and thus allowing for precise analysis of functional endpoints and more accurate prediction of drug sensitivity. In summary, HuBiogel-based tumor models will positively impact cancer research, drug discovery, and therapeutic arenas. (Supported by CA-108118 & CB-56601)
Comparing progression-free survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods.
Authors: Venediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, K. Jack Ishak, Hemant Phatak, Vijay Kasturi, Ting Yu, Murtuza Bharmal
Journal: Journal of Clinical Oncology (2020)

573 Background: Population-adjusted comparisons of PFS from single-arm trials of cancer treatments can be derived using matching-adjusted indirect comparison (MAIC); however, results are still susceptible to bias, particularly if the trials had different tumor assessment schedules (favoring longer intervals). This is shown with an MAIC of avelumab vs atezolizumab, nivolumab, durvalumab, pembrolizumab or chemotherapy in 2L UC. Methods: The MAIC used patient-level data for avelumab from the JAVELIN Solid Tumor trial (NCT01772004) and compared PFS with published curves for other treatments to obtain population-adjusted hazard ratios (HRs). The first assessment was scheduled at 6 weeks for avelumab and durvalumab and at 8 or 9 weeks for the others. The MAIC was repeated after aligning the first assessment time for avelumab to each comparator’s schedule with the Assessment Schedule Matching (ASM) method. Results: Naïve analyses (Table) suggest similar PFS for avelumab vs comparators. MAIC based on population adjustment (PA) altered the HR of avelumab vs atezolizumab and nivolumab (23.0% and 9.2% reductions in HR, respectively) but had little effect in other comparisons. ASM adjustment led to further changes in HR (13.2-32.7% reductions from naïve) favoring avelumab in MAICs where schedules differed. Of note, assessment schedule differences fully accounted for differences in PFS between avelumab and pembrolizumab. Conclusions: Indirect comparisons of PFS from single-arm trials must include adjustment for differences in both population characteristics and tumor assessment schedules. In this 2L UC MAIC, adjustment reversed some naïve comparisons, revealing more favorable PFS with avelumab up to 30%. Clinical trial information: NCT01772004. [Table: see text]
The Evolution of Schools of Thought in Medicine
Authors: C. David Naylor
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results from the <i>BJD</i> survey on readership views towards clinical practice guidelines
Authors: Z.Z.N. Yiu, Z.K. Jabbar‐Lopez, S. Ahmed, M.F. Mohd Mustapa, C.‐C. Chi, C. Flohr
Journal: British Journal of Dermatology (2020)

Linked Editorial: Yiu et al. Br J Dermatol 2020; 183:1–2.
Ipilimumab (IPI) Expanded Access Program (EAP) for Patients (PTS) with Stage III/IV Melanoma: Safety Data by Subgroups
Authors: D. Lawrence, D.F. McDermott, O. Hamid, J.S. Weber, J.D. Wolchok, J. Richards, A. Amin, K. Bennett, A. Balogh, F.S. Hodi
Journal: Annals of Oncology (2012)
Lipid‐Modified Aminoglycosides for mRNA Delivery to the Liver
Authors: Xueliang Yu, Shuai Liu, Qiang Cheng, Tuo Wei, Sang Lee, Di Zhang, Daniel J. Siegwart
Journal: Advanced Healthcare Materials (2020)

Cationic lipid nanoparticles (LNPs) are widely used as carriers for delivery of nucleic acids. Most synthetic routes toward cationic lipids have derived from simple amine cores. Greater chemical diversity can be obtained through starting with natural products containing basic nitrogen atoms, which offers routes to more complex molecules. Natural building blocks are not extensively explored, such as aminoglycosides, which are both structurally and functionally interesting for developing new carriers for nucleic acid delivery. Herein, cationic lipid-modified aminoglycosides (CLAs) are explored as a family of vehicles for messenger RNA (mRNA) delivery. CLAs are synthesized from natural existing aminoglycosides coupling with alkyl epoxides and acrylates. The top hit (GT-EP10) is able to deliver Luc mRNA to C57BL/6 mice at a dose of 0.05 mg kg
Coronavirus 2019-nCoV: A brief perspective from the front line
Authors: Qingmei Han, Qingqing Lin, Shenhe Jin, Liangshun You
Journal: Journal of Infection (2020)

A novel coronavirus, designated as 2019-nCoV, hit the central Chinese city of Wuhan in late December 2019, and subsequently spread rapidly to all provinces of China and multiple countries. As of 0:00 am February 9, 2020, a total of 37,287 cases have been confirmed infection of 2019-nCoV in China mainland, and 302 cases have also been cumulatively reported from 24 countries. According to the latest data, a total of 813 deaths occurred in China mainland, with the mortality reaching approximately 2.2%. At present, there is no vaccine or specific drugs for the human coronavirus. Therefore, it is critical to understand the nature of the virus and its clinical characteristics, in order to respond to the 2019-nCoV outbreak. Thus, the present study briefly but comprehensively summarizes the not much but timely reports on the 2019-nCoV.
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease
Authors: Jacob E. Ollech, Inessa Normatov, Noam Peleg, Jingzhou Wang, Shivani A. Patel, Victoria Rai, Yangtian Yi, Jorie Singer, Sushila R. Dalal, Atsushi Sakuraba, Russell D. Cohen, David T. Rubin, Joel Pekow
Journal: Clinical Gastroenterology and Hepatology (2020)
‘Training load error’ is not a more accurate term than ‘overuse’ injury
Authors: Judd Kalkhoven, Aaron James Coutts, Franco M Impellizzeri
Journal: British Journal of Sports Medicine (2020)

It has been proposed to bin the term ‘overuse’ injury and replace it with ‘training load error’ as a more accurate term.1 There are several concerns with this proposal. To warrant a name change, the new name should provide additional benefit beyond that which overuse currently provides, be based on reasonable and sound arguments and assumptions, and be coherent with the best practice and evidence available.

Training load is just one factor among an array of factors that may contribute to overuse injury occurrence, as has been highlighted in more complex models.2 Defining overuse injuries as training load errors is a negation of their multifactorial nature. If training load error was to be adopted, this would not be a question of defining an event by its mechanisms, but defining the event by arbitrary picking one of the potential antecedent causal factors among different levels of the injury causal pathway. Such misuse of terminology may provide temptation to rename reinjury occurrence when returning to play or training as ‘physiotherapy error’ injuries, various intraoperative …
Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes
Authors: Shanshan Shen, Hui Luo, Cicily Vachaparambil, Parit Mekaroonkamol, Mohamed M. Abdelfatah, Guifang Xu, Huimin Chen, Liang Xia, Hong Shi, Steve Keilin, Field Willingham, Jennifer Christie, Edward Lin, Qiang Cai
Journal: Endoscopy (2020)

Background Gastric peroral endoscopic pyloromyotomy (G-POEM) and gastric electrical stimulation (GES) have been reported as treatment options for refractory gastroparesis. In this study, we compared the long term clinical outcomes of G-POEM versus GES in the treatment of such patients. Methods We retrospectively evaluated 111 consecutive patients with refractory gastroparesis between January 2009 and August 2018. To overcome selection bias, we used propensity score matching (1:1) between G-POEM and GES treatment. The primary outcome was the duration of clinical response. Results After propensity score matching, 23 patients were included in each group. After a median follow-up of 27.7 months, G-POEM had a significantly better and longer clinical response than GES (hazard ratio [HR] for clinical recurrence 0.39, 95 % confidence interval [CI] 0.16 – 0.95; P = 0.04). The median duration of response was 25.4 months (95 %CI 8.7 – 42.0) in the GES group and was not reached in the G-POEM group. The Kaplan – Meier estimate of 24-month clinical response rate was 76.6 % with G-POEM vs. 53.7 % with GES. GES appeared to have little effect on idiopathic gastroparesis (HR for recurrence with G-POEM vs. GES 0.35, 95 %CI 0.13 – 0.95; P = 0.05). The incidence of adverse events was higher in the GES group (26.1 % vs. 4.3 %; P = 0.10). Conclusion Among patients with refractory gastroparesis, clinical response was better and lasted longer with G-POEM than with GES. The positive outcomes with G-POEM are likely to derive from the superior clinical response in patients with idiopathic gastroparesis. Further studies are needed to confirm these findings.
T-cell lymphoma secondary to checkpoint inhibitor therapy
Authors: Kartik Anand, Joe Ensor, Sai Ravi Pingali, Patrick Hwu, Madeleine Duvic, Stephen Chiang, Roberto Miranda, Youli Zu, Swaminathan Iyer
Journal: Journal for ImmunoTherapy of Cancer (2020)

Murine model suggests programmed cell death-1 (PD-1), an immune checkpoint not only plays role in tumor escape but is also a tumor suppressor for T-cells. But until, no reports of secondary T-cell lymphoma postuse of immune checkpoint inhibitors (ICIs) has been reported. Herein, we present a hitherto unreported phenomenon of secondary T-cell lymphoma when PD-1 inhibitor was used in a patient diagnosed with a tumor of epithelial origin.
Adjunctive Vitamin D2 Supplement in Patient with Allergen-Specific Immunotherapy Randomized, Double Blind, Placebo-Controlled Trial
Authors: Chirawat Chiewchalermsri, Sasipa Sangkanjanavanich, Panitan Pradubpongsa, Wat Mitthamsiri, Nattapon Jaisupa, Atik Sangasapaviliya, Tadech Boonpiyathad
Journal: Journal of Allergy and Clinical Immunology (2020)
Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancer
Authors: Leisl M Packer, Sara Byron, David Loch, Farhad Dehkhoda, Andreas Wortmann, Xinyan Geng, Katia Nones, Sean Grimmond, John Pearson, Nic Waddell, Pamela Pollock
Journal: Cancer Research (2014)
Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles
Authors: Xiuli Zhang, Feng Chen, Melik Z. Turker, Kai Ma, Pat Zanzonico, Fabio Gallazzi, Manankumar A. Shah, Austin R. Prater, Ulrich Wiesner, Michelle S. Bradbury, Michael R. McDevitt, Thomas P. Quinn
Journal: Biomaterials (2020)
Dendritic Cell Immunoreceptor (DCIR) Modulates Cockroach Allergen-Induced Atopic Dermatitis through Regulating Mast Cell Activation
Authors: Jingsi Chen, Huan Yang, Xiaoyan Luo, Xinyue Hu, Danh Do, Nathan Archer, Hua Wang, Lloyd Miller, Peisong Gao
Journal: Journal of Allergy and Clinical Immunology (2020)
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy
Authors: Cem Akin, Hanneke Oude Elberink, Jason Gotlib, Vito Sabato, Karin Hartmann, Sigurd Broesby-Olsen, Mariana Castells, Michael Deininger, Mark Heaney, Tracy George, Deepti Radia, Massimo Triggiani, Paul van Daele, Daniel DeAngelo, Oleg Schmidt-Kittler, Hui-Min Lin, Andrew Morrison, Brenton Mar, Frank Sibenhaar, Marcus Maurer
Journal: Journal of Allergy and Clinical Immunology (2020)
Abstract 12318: Effects of Dietary Sodium Reduction on Metabolomic Profiles in Untreated Black Hypertensives
Authors: Li Chen, Feng J. He, Yanbin Dong, Gregory A. Harshfield, Haidong Zhu
Journal: Circulation (2018)

Introduction: Dietary sodium reduction has multiple beneficial effects on cardiovascular health. However, the underlying mechanisms are not fully understood, and the effect of sodium reduction on m...
Is Home Challenge An Option in Food Protein-Induced Enterocolitis Syndrome? Natural History Of FPIES And Results Of Home Allergen Re-challenge
Authors: Kristiina Frechette, Vaidehi Bhatt, Maya Al Mardini, Tarin Moni, Wardha. Wardha, Vince Wu, Jason Ohayon
Journal: Journal of Allergy and Clinical Immunology (2020)
Lymph node metastasis to predict overall survival in oligometastatic prostate cancer in Asian patients.
Authors: Junryo Rii, Shinichi Sakamoto, Yasutaka Yamada, Yusuke Imamura, Kazuyoshi Nakamura, Akira Komiya, Hiroomi Nakatsu, Tomohiko Ichikawa
Journal: Journal of Clinical Oncology (2020)

237 Background: The oligometastatic cancer has been suggested as an intermediate state between localized disease and wide range metastases. Clinical significance of local treatment in oligometastatic prostate cancer (PCa) has been a recent topic. However, due to racial differences, there are no standard definitions of oligometastasis, especially in Asians. Here we studied the risk factor among Japanese oligometastatic PCa patients. Methods: We retrospectively analyzed the medical record of 207 patients, including locally advanced (T3 or T4N0M0), lymph-node-positive (N1), and ≤10 bone metastases cancer. All patients received androgen deprivation therapy only. The number of bone metastasis and clinical factors were evaluated in association with OS. Results: Median age, PSA at baseline and OS were 73 years, 48.8ng/ml and 121 months respectively. The cutoff value for the number of bone metastases that have the greatest impact on OS was ≥2 (HR 3.05, p = 0.0001), followed by ≥7 (HR 3.03, p = 0.0005). In multivariate analysis, lymph node metastasis (HR 2.54, p = 0.003) and ≥2 bone metastases (HR 2.67, p = 0.009) were independent predictors of OS. In risk classification based on independent predictors, OS was significantly classified in High (3-4 factors), Intermediate (1-2 factors), and Low (no factor) risk groups (p &lt;0.0001). Furthermore, even among same risk factors group, inclusion of lymph node metastasis significantly increased the HR by 2.34 (p = 0.039). Conclusions: Not only the number of bone metastasis but also lymph node metastasis predict OS of oligometastatic PCa patients.[Table: see text]
Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19
Authors: Charles Calisher, Dennis Carroll, Rita Colwell, Ronald B Corley, Peter Daszak, Christian Drosten, Luis Enjuanes, Jeremy Farrar, Hume Field, Josie Golding, Alexander Gorbalenya, Bart Haagmans, James M Hughes, William B Karesh, Gerald T Keusch, Sai Kit Lam, Juan Lubroth, John S Mackenzie, Larry Madoff, Jonna Mazet, Peter Palese, Stanley Perlman, Leo Poon, Bernard Roizman, Linda Saif, Kanta Subbarao, Mike Turner
Journal: The Lancet (2020)